英文発表論文
5. 自己免疫疾患と関連したヒト自己抗原とHLAおよびT細胞の解析
- Sakisaka,M., et al.
Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β. Journal of Hepato-Biliary-Pancreatic Sciences (in press) - Imamura, Y., et al.,
Generation of large numbers of antigen-expressing human dendritic cells using CD14-ML technology. PLoS ONE 11 (4), e0152384, 2016. - Miyashita, A., et al.
Immunotherapy against Metastatic Melanoma with Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons. Cancer Immunol Res. 3: 248-258, 2016. - Zhang, R., Liu, et al.
Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells. Cancer Immunology Research 3: 668-677, 2015 - Motoshima T, et al.
CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma. Oncology Letter, 2015 in press - Senju, S., et al.
Application of iPS cell-derived macrophages to cancer therapy. OncoImmunology, 3:e27927-1-3, 2014 - Haga, E., et al.
Therapy of peritoneally disseminated colon cancer by TAP-deficient ES cell-derived macrophages in allogeneic recipients Journal of Immunology, 193:2024-2033, 2014 - Ikeda, T., et al.
Suppression of Th1-mediated autoimmunity by embryonic stem cell-derived dendritic cells. PLoS One 18:e115198, 2014 - Takamatsu, K., et al.
Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2 Stem Cell Research 13:442-453, 2014 - Koba, C. et al.
Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-b against peritoneally disseminated cancer in xenograft models
PLOS ONE, e67567, 2013 - Haruta, M. et al.
Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1
Human Immunology 74: 1400-1408, 2013 - Senju, S. et al.
Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy
Gene Therapy advance online publication, 24 March 2011 - Ikeda, T. et al.
Dual effects of TRAIL to suppress autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells
J.Immunol. 185:5259-5267, 2010 - Senju, S. et al.
Pluripotent stem cells as source of dendritic cells for immune therapy
Int.J.Hematol. 91:392-400, 2010 - Senju, S. et al.
Pluripotent stem cell-derived dendritic cells for immunotherapy
Frontiers in bioscience (Elite edition) 2, 1520-1527, 2010 - Senju, S. et al.
Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent
Stem cells, 27:1021-1031, 2009 - Fukushima, S. et al.
Multiple antigen-targeted immunotherapy with a-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells
J.Immunotherapy, 32:219-231, 2009 - Matsunaga, Y. et al.
Activation of antigen-specific cytotoxic T lymphocytes by b2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic ES cell-derived dendritic cells
J.Immunol. 181:6635-6643, 2008 - Senju, S. et al.
Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function
Stem cells, 25:2720-2729, 2007 - Hirata, S. et al.
Involvement of regulatory T cells in the experimental autoimmune encephalomyelitis-preventive effect of dendritic cells expressing myelin oligodendrocyte glycoprotein plus TRAIL
J.Immunol. 178:918-925, 2007 - Motomura, Y.et al.
Embryonic stem cell-derived dendritic cells expressing Glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10
Cancer Research, 66:2414-2422, 2006 - Matsuyoshi, H.et al
Therapeutic effect of a-galactosylceramide loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells
Cancer Science, 96:889-896, 2005 - Fukuma, D. et al.
Cancer prevention with semi-allogeneic ES cell-derived dendritic cells
Biochem. Biophys. Res. Comm. 335:5-13, 2005 - Hirata, S. et al.
Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand1
J.Immunol. 174:1888-1897, 2005 - Matsuyoshi, H. et al.
Cancer immunotherapy by genetically modified embryonic stem cell-derived dendritic cells
In immunology 2004 (The proceeding of the 12th International Congress of Immunology, ed. By Skamene, E.) Medimond S.r.l. (Bologna, Italy), p487-491, 2004 - Matsuyoshi, H. et al.
Enhanced priming of antigen-specific CTL in vivo by transfer of ES cell-derived dendritic cells expressing chemokine along with antigenic protein； application to anti-tumor vaccination
J.Immunol. 172:776-786, 2004 - Senju, S. et.al.
Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells
Blood, 101:3501-3508, 2003 - Masuda, M. et al.
Identification and immunocytochemical analysis of DCNP1, a dendritic cell-associated nuclear proteinBiochem
Biochem. Biophys. Res. Comm. 290:1022-1029, 2002 - Senju S, et al.
Immunocytochemical analyses and targeted gene disruption of GTPBP1
Mol Cell Biol. 20:6195-6200, 2000
PMID: 10938096; UI: 20396297 - Kudo H, et al.
Mouse and human GTPBP2, newly identified members of the GP-1 family of GTPase
Biochem Biophys Res Comm. 272:456-465, 2000 - Senju S, et al.
Identification of human and mouse GP-1, a putative member of a novel G-protein family. Biochem Biophys Res Comm. 231:360-364, 1997
- Tsukamoto H*, Fujieda K*,et al. (*equal contribution)
Soluble IL-6R expressed by myeloid cells reduces tumor-specific Th1 differentiation and drives tumor progression.Cancer Res. (in press) 2017. DOI: 10.1158/0008-5472.CAN-16-2446 - Hirayama, M., et al.
The present status and future prospects of peptide-based cancer vaccines. Int. Immunol. 28: 319-328, 2016. - Hirayama, M., et al.
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. OncoImmunology 5:e1123368. 2016., - Sayem, M.A., et al.
Identification of Glypican-3-derived long peptides activating both CD8+ and CD4+ T-cells; Prolonged overall survival in cancer patients with Th cell response. OncoImmunology 5: e1062209., 2016. - Motoshima, T., et al.
CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.Onco Lett, 11:1911-1916, 2016. - Yoshitake, Y., et al.
A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS. OncoImmunology, 4: e1022307, 2015 - Nishimura, Y., et al.
Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. Cancer Science 106:505-511, 2015 - Tsukamoto, H., et al.
IL-6-mediated environmental conditioning of defective Th1 differentiation dampens anti-tumor immune responses in old age. Nature communications 6:6702, 2015 - Yoshitake , Y., et al.
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin. Cancer Research 21:312-321, 2015 - Tomita, Y.*, Yuno, A.*, et al. (*equal contribution)
LY6K-specific CD4+ T-cell immunity in patients with malignant tumor: Identification of LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes. OncoImmunology 3:e28100-1-15, 2014 - Inaguma, Y., et al.
Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Therapy 21:575-584, 2014 - Sawada Y., et al.
Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncology Reports 31:1051-1058, 2014 (Open access) - Yatsuda, J.*, Irie, A.*, et al.(*equal contribution)
Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens. PLOS ONE 8:e84908, 2013 - Tomita, Y., and Nishimura, Y.
Long peptides-based cancer immunotherapy targeting tumor antigen-specific CD4+ and CD8+ T cells Oncoimmunology 2: e25801, 2013 - Tomita, Y., Yuno, A. et al.
Identification of CDCA1 long peptides bearing both CD4+and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer petients
Int. J. Cancer 134: 352-366, 2014 - Tomita, Y., Yuno, A. et al.
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor
Clinical Cancer Research 19: 4508-4520, 2013 - Tsukamoto, H et al.
Myeloid-derived suppresor cells attenuate Th1 development through IL-6 production to promote tumor progression
Cancer Immunol. Res. in press - Horlad, H et al.
Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells
Mol. Nutr. Food Res. 18, in press, 2013 - Tomita, Y et al.
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T lymphocytes reactive to tumor cells
Cancer Science, 102:697-705, 2011 - Imai, K et al.
Identification of HLA-A2-restricted CTL epitopes of a novel tumor-associated antigen, KIF20A, overexpressed in pancreatic cancer
Brit. J. Cancer, 104:300-307, 2011 - Tomita, Y et al.
Peptides derived from human insulin-like growth factor (IGF)-II mRNA binding protein 3 can induce human leukocyte antigen-A-2-restricted cytotoxic T lymphocytes reactive to cancer cells
Cancer Science, 102:71-78, 2011 - Inoue, M. et al.
Identification of SPARC as a candidate target antigen for immunotherapy of various cancers
Int. J. Cancer, 127:1393-1403,2010 - Yokomine, K. et al.
The Forkhead Box M1 Transcription Factor, as a Possible Immunotherapeutic Tumor-Associated Antigen
Int. J. Cancer, 126:2153-2163, 2010 - Inoue, M. et al.
An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL 2rgamma null (NOG) mice
Immunol. Lett. 126:67-72, 2009 - Yoshiaki Ikuta*,Yuki Hayashida*. et al.
Identification of the H2-Kd-restricted CTL epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice
Cancer Science, 100:132-137, 2009 - Imai, K. et al.
Identification of a novel tumor-associated antigen, Cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric and colorectal cancers
Clin. Cancer Res. 14:6487-6495, 2008 - Harao, M. et al.
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL
Int. J. Cancer, 123:2616-2625, 2008 - Motomura, Y. et al.
HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice
Int. J. Oncol. 32:985-990, 2008 - Yokomine, K. et al.
Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in ApcMin/+ mice
Cancer Science, 98:1930-1935, 2007 - Komori, H. et al.
Identification of HLA-A2- or HLA-A 24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
Clin. Cancer Res. 12:2689-2697, 2006 - Hosaka, S. et al.
Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitroand invivo
Cancer Science, 97:623-632, 2006 - Yokomine, K.et al.
Immuniztion with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice
Biochem. Biophys. Res. Comm. 343:269-278, 2006 - Motomura, Y.et al
Embryonic stem cell-derived dendritic cells expressing Glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10
Cancer Research, 66:2414-2422, 2006 - Ikuta, Y. et al.
Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels.
Clinical Cancer Research, 11:8079-8088, 2005 - Guo , Y. et al.
Direct recognition and lysis of leukemia cells by WT1-specific CD4+T lymphocytes in an HLA class II-restricted manner
Blood, 106:1415-1418, 2005. - Miyazaki, M.*, Nakatsura, T.*(*Equal contribution
DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4+T cells and CD8+T cells
Cancer Science, 96:695-705, 2005 - Nakatsura, T. et al.
Mouse homologue of a novel human oncofetal antigen, Glypican-3, evokes T cell-mediated tumor rejection without autoimmune reactions in mice
Clinical Cancer Research, 10:8630-8640, 2004 - Yoshitake, Y. et al.
Proliferation potential-related protein, an ideal esophageal cancer antigen for immnotherapy, identified using cDNA microarray analysis
Clinical Cancer Research, 10:6437-6448, 2004 - Monji, M. et al.
Identification of a novel cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses
Clinical Cancer Research, 10:6047-6057, 2004 - Nakatsura, T. et al.
Identification of Glypican-3 as a Novel Tumor Marker for Melanoma
Clinical Cancer Research, 10:6612-6621, 2004 - Kobayashi, H. et al.
Identification of Naturally Processed Helper T-Cell Epitopes from Prostate-Specific Membrane Antigen Using Peptide-Basedin Vitro Stimulation
Clinical Cancer Research, 9:5386-5393, 2003 - Kai, M. et al.
Heat shock protein 105 is overexpressed in a variety of human tumors
Oncology reports, 10:1777-1782, 2003 - Nakatsura, T. et al.
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
Biochem. Biophys. Res. Comm. 306:16-25, 2003 - Monji, M. et al.
Head andneck cancer antigens recognized by the humoral immune system
biochem. biophys. 294:734-741, 2002 - Nakatsura, T. et al.
Cellular and Humoral Immune Responses to A Human Pancreatic Cancer Antigen, CLP, Originally Defined by the SEREX Method
Eur. J. Immunol. 32:826-836, 2002 - Nakatsura, T. et al.Gene cloning of immunogenic antigens over-expressed in pancreatic cancer
Biochem Biophys Res Comm. 281:936-944, 2001 - Maeda A, et al.
Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, cancer-associated retinopathy antigen, to achieve a clinical better prognosis in a paraneoplastic syndrome
Eur J Immunol. 31:563-572, 2002 - Yasukawa M, et al.
Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia
J.Hematol. 63:99-101, 2000
PMID: 10629577; UI: 20096462 - Yun C, et al
Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein
Tissue Antigens, 54:153-161, 1999 - Yasukawa M, et al.
CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner
Blood, 92:3355-3361, 1998 - Tanaka Y, et al.
Efficient induction of human CD4+ T cell lines reactive with a self-K-ras-derived peptide in vitro, using a mAb to CD29
Hum Immunol.59:343-351, 1998 - Fujita H, et al.
Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms
Eur J Immunol. 28:305-316, 1998 - Zeki K, et al.
Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53
Int J Cancer. 75:391-395, 1998
PMID: 9455799; UI: 98115334 - Yokomizo H, et al.
Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides
Hum Immunol. 52:22-32, 1997
- Irie, A. et al.
Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A
PLOS ONE, on line, 2012 - Tsukamoto, H.et al.
B-Raf-mediated signaling pathway regulates T cell development
Eur.J.Immunol. 38:518-527, 2008 - Irie, A. et al.
Protein kinase D2 contributes to either IL-2 promoter regulation or induction of cell death upon TCR-stimulation depending on its activity in Jurkat cells
Int.Immunol. 18:1737-1747, 2006 - Ohnishi, Y. et al.
Altered peptide ligands control type II collagen-reactive T cells from rheumatoid arthritis patients
Mod. Rheumatol. 16:226-228, 2006 - Tsukamoto, H.et al.
TCR ligand avidity determines the mode of B-Raf/Raf-1/ERK activation leading to the activation of human CD4+T cell clone
Eur.J.Immunol. 36:1926-1937, 2006 - Kim, J-R.et al.
A role of kinase inactive ZAP-70 in altered peptide ligand stimulated T cell activation
Biochem.Biophys.Res.Comm. 341:19-27, 2006 - Chen, Y-Z.et al.
Coculture of Th cells with IL-7 in the absence of antigenic stimuli induced T cell anergy reversed by IL-15
Human Immunol. 66:677-687, 2005 - Tsukamoto, H. et al.
B-Raf contributes to sustained extracellular signal-regulated kinase activation associated with interleukin-2 production stimulated through the T cell receptor
J.Biol.Chem. 279:48457-48465, 2004 - Nishimura, Y.et al..
Review, Degenerate recognition and response of human CD4+Th cell clones: Implications for basic and applied immunology
Mol. Immunol. 40:1089-1094, 2004 - Irie, A . et al. .
Unique T-cell proliferation associated with PKCu activation and impaired Zap-70 phosphorylation in recognition of overexpressed HLA-DR/partially agonistic peptide complexes
Eur.J.Immunol. 33:1497-1507, 2003 - Uemura, Y. et al.
[Review] Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-class II restricted T cell receptors; Implications for clinical medicine.
Modern Rheumatology, 13:205-214, 2003 - Uemura, Y. et al..
Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for GAD65 specific TCRs
J.Immunol. 170:947-960, 2003 - Kudo, H. et al.
Cross-linking HLA-DR molecules on Th1 cells induces anaergy in association with increased level of cyclin-dependent kinase inhibitor p27Kip1.
Immunol. Letters, 81:149-155, 2002 - Fujii, S./Uemura, Y. et al.
Establishment of an expression cloning system for CD4+T cell epitopes.
Biochem.Biophys.Res.Comm. 284:1140-1147, 2001 - Tabata H, et al. .
Ligation of HLA-DR molecules on B cells induces enhanced expression of IgM heavy chain genes in association with Syk activation.
J Biol Chem. 275:34998-35005, 2000 - Lai ZF, Chen YZ, et al. .
An amiloride sensitive and voltage-dependent Na+ channel in a HLA-DR-restricted human T cell clone.
J.Immunol. 165:83-90, 2000
PMID: 10861038; UI: 20318702 - Tanaka Y, et al.
Identification of Peptide Superagonists for a Self-K-ras-Reactive CD4+ T Cell Clone Using Combinatorial Peptide Libraries and Mass Spectrometry.
J.Immunol. 162:7155-7161, 1999 - Chen YZ, et al.
Modulation of calcium responses by altered peptide ligands in a human T cell clone.
Eur J Immunol. 28:3929-39, 1998 - Nishimura Y, et al.
Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification.
Intern Med. 37:804-17, 1998 - Fujii S, et al.
The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Hum Immunol. 59:607-14, 1998 - Matsushita S, et al.
Evidence for self and nonself peptide partial agonists that prolong clonal survival of mature T cells in vitro.
J Immunol. 158:5685-91, 1997 - Chen YZ, et al.
A single residue polymorphism at DR beta 37 affects recognition of peptides by T cells.
Hum Immunol. 54:30-39, 1997 - Matsushita S, et al.
Partial activation of human T cells by peptide analogs on live APC: induction of clonal anergy associated with protein tyrosine dephosphorylation.
Hum Immunol. 53:73-80, 1997 - Matsuoka T, et al.
Altered TCR ligands affect antigen-presenting cell responses: up-regulation of IL-12 by an analogue peptide.
J Immunol. 157:4837-43, 1996 - Chen YZ, et al.
Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation.
J Immunol. 157:3783-90, 1996 - Ikagawa S, et al.
Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism.
J Allergy Clin Immunol.97(1 Pt 1):53-64, 1996
- Chen Y-Z, et al.
Identification of SARS-CoV spike protein-derived and HLA-A2-restricted human CTL epitope by using a new muramyl dipeptide-derivative adjuvant.
International Journal of Immunopathology and Pharmacology, 23:165-177, 2010 - Fukunaga T. et al.
Relation between CD4(+) T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Am J Cardiol. 100:483-488, 2007 - Fukunaga T. et al.
Expression of interferon-gand interleukin-4 production in CD4(+) T cells in patients with chronic heart failure.
Heart and Vessels. 22:178-83, 2007 - Soejima H. et al.
Elevated plasma osteopontin levels were associated with osteopontin expression of CD4(+) T cells in patients with unstable angina.
Circ. J. 70:851-856, 2006 - Tanaka, T. et al.
Comparison of frequency of interferon-gamma-positive CD4+ T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris.
Am. J. Cardiol. 93:1547-1549, 2004 - Soejima, H. at al..
The preference to a Th1-type response in patients with coronary spastic angina.
Circulation, 107:2196-2200, 2003 - Inoue, R. et al.
Identification ofb-lactoglobulin-derived peptides and class II HLA molecules recognized by T Cells from patients with milk allergy.
Clin Exp Allergy. 31:1126-1134, 2001 - Ohyama H, et al.
T cell responses to 53-kDa outer membrane protein of Porphyromonas gingivalis in humans with early-onset periodontitis.
Hum Immunol. 59:635-43, 1998
5. 自己免疫疾患と関連したヒト自己抗原とHLAおよびT細胞の解析
- Ueda, S.*, Oryoji, D.*, Yamamoto K.*, et al. (*equal contribution)
Identification of independent susceptible and protective HLA alleles in Japanese autoimmune thyroid disease and their epistasis.J Clin Endocrinol Metab 99: E379-383, 2014. - Yano, T. et.al.
Autoimmunity against neurofilament protein and its possible association with HLA-DRB1*1502 allele in glaucoma.
Immnol. Lts. 100:164-169, 2005 - Ohkura, T. et al.
Detection of the novel autoantibody (anti-UACA antibody) in patients with Graves disease.
Biochem. Biophys. Res. Comm. 321:432-440, 2004 - Yamada, K . et al.
Humoral immune response directed against LEDGF in patients with VKH.
Immunol. Letters, 78:161-168, 2001 - Nishimura, Y. et al.
(review) Molecular and cellularanalyses of HLA class II – associated susceptibility to autoimmune diseases in the Japanese population
Modern Rheumatology, 11:103-112, 2001 - Minohara, M. et al.
Differences between T cell reactivities to major myelin protein-derived peptides in opticospinal and conventional forms of multiple sclerosis and healthy controls.
Tissue Antigens, 57:447-456, 2001 - Tsuchiya, K.et al.
Combination of HLA-A andHLA class II alleles controls the susceptibility to rheumatoid arthritis.
Tissue Antigens, 58:395-401, 2001 - Yamada, K.et al.
Identification of a novel autoantigen UACA in patients with panuveitis.
Biochem Biophys Res Comm. 280:1169-1176, 2001 - Shigematsu H, et al.
Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognitionamong mitochondrial autoantigens
Hepatology, 32:901-909, 2000 - Ito H, et al.
Analysis of T cell responses to the b2-glycoprotein I-derived peptide library in patients with anti-b2-glycoprotein I antibody-associated autoimmunity
Hum Immunol. 61:366-377, 2000 - Fukazawa T, et al.
Both the HLA-DPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: Clinical phenotypes and gender as important factors
Tissue Antigens. 55:199-205, 2000 - Yamasaki K, et al.
HLA-DPB1*0501-associated optico-spinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies
Brain, 122(Pt 9):1689-1696, 2000 - Nishimura Y, et al.
Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune diseases
Int Rev Immunol. 17(5-6):229-262, 1998 - Ono T, et al.
Molecular analysis of HLA class I (HLA-A and -B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis
Tissue Antigens. 52:539-542, 1998 - Tabata H, et al.
Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus
Hum Immunol. 59:549-560, 1998 - Ito H, et al.
HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese
Tissue Antigens. 52:179-182, 1998 - Kanai T, et al.
Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor alpha subunit peptide presented by the disease-susceptible HLA-DQ6 in infant-onset myasthenia gravis
Hum Immunol. 56(1-2):28-38, 1997 - Nishimura Y, et al.
Molecular mechanisms underlying HLA-DR-associated susceptibility to autoimmunity
Int J Cardiol. 54 Suppl:S81-590, 1996
PMID: 9119530; UI: 97120288. - Kira J, et al.
Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders
Ann Neurol. 40:569-574, 1996
PMID: 8871575; UI: 97025385.
- Kusano, S., et al.
Structural basis for the specific recognition of the major antigenic peptide from the Japanese cedar pollen allergen Cry j 1 by HLA-DP5. J. Mol.Biol. 426: 3016-3027, 2014 - Oiso M, et al.
Differential binding of peptides substituted at putative C-terminal anchor residue to HLA-DQ8 and DQ9 differing only at beta 57
Hum Immunol. 52:47-53, 1997 - Fujisao S, et al.
Evaluation of peptide-HLA binding by an enzyme-linked assay and its application to the detailed peptide motifs for HLA-DR9 (DRB1*0901).
J Immunol Methods. 201:157-63, 1997 - Oiso M, et al.
Differential binding of peptides substituted at a putative C-terminal anchor residue to I-Ag7beta56Hisbeta57Ser and I-Ag7beta56Probeta57Asp
Immunogenetics, 47:411-414, 1996 No abstract available
[Record as supplied by publisher]
PMID: 9510560. - Matsushita S, et al.
HLA-DQ-binding peptide motifs. 1. Comparative binding analysis of type II collagen-derived peptides to DR and DQ molecules of rheumatoid arthritis-susceptible and non-susceptible haplotypes
Int Immunol. 8:757-764, 1996 - Fujisao S, et al.
Identification of HLA-DR9 (DRB1*0901)-binding peptide motifs using a phage fUSE5 random peptide library
Hum Immunol. 45:131-136, 1996 - Matsushita S, et al.
Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome
J.Exp.Med. 180:873-83, 1994
- Ishimura, R. et al.
Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration. Science 345:455-459, 2014
